Bendamustine (Exinda)

N/A

Report date: 2024/09/27 09:14:48

Base Information

Drug NameBendamustine (Exinda)
Drug Alias NameBendamustine oral (Exinda)EX-103 (Exinda)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAlkylating agentsDNA cross linking agents
TargetsDNA
Therapy Area/IndicationsLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesExinda Therapeutics LL
China Registration ClassN/A

Develop Information

Active CompaniesExinda Therapeutics LL
Inactive CompaniesN/A
Active IndicationsLeukemia, Lymphocytic, Chronic, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A